HomeSearch for 'From'

From - News and Articles about commonly prescribed drugs

Biogen and Eisai current detailed outcomes from section 1b examine of aducanumab at CTAD assembly

Posted in News on 8th November 2018

Biogen and Eisai Co., Ltd. introduced that Biogen introduced outcomes on the Medical Trials on Alzheimer’s Illness (CTAD) assembly, in Barcelona, Spain, from the current 36- and 48-month analyses of the continuing long-term extension (LTE) of the Section 1b examine of aducanumab, an investigational therapy for gentle cognitive impairment (MCI) as a consequence of Alzheimer’s illness (AD) and gentle AD.

A late-breaking oral presentation and a poster included knowledge from sufferers handled with aducanumab for as much as 36 and 48 months. Knowledge from each analyses confirmed a discount in amyloid plaque ranges in a dose- and time-dependent method, as measured by positron emission tomography (PET). As well as, analyses of exploratory medical endpoints, Medical Dementia Score Sum of Containers (CDR-SB) and the Mini-Psychological State Examination (MMSE), prompt a continued slowing of medical decline over 36 months and 48 months. The leads to every dosing arm had been usually according to beforehand reported analyses of this examine, and there have been no modifications to the risk-benefit profile of aducanumab.

“This Section 1b examine now has 4 years of aducanumab outcomes, and we’re inspired by these knowledge, which continued to indicate a discount in amyloid plaque ranges and counsel our investigational remedy might gradual medical development of the illness,” stated Alfred Sandrock, Jr., M.D., Ph.D., govt vp and chief medical officer at Biogen. “The Section three research are actually absolutely enrolled, and we stay pushed by the profound unmet wants of sufferers, households, caregivers and society.”​

Supply:

https://www.eisai.com/information/2018/information201894.html

Hormone injections scale back danger for early menopause from breast most cancers chemotherapy

Posted in News on 7th November 2018

Ultimate outcomes of SWOG Most cancers Analysis Community’s groundbreaking worldwide Prevention of Early Menopause Research (POEMS) medical trial are in, they usually present continued proof that girls who get injections of the hormone drug goserelin together with normal breast most cancers chemotherapy usually tend to turn out to be pregnant – with out creating detrimental unintended effects or shortening their lives.

“These five-year follow-up outcomes affirm our preliminary findings,” stated SWOG investigator Halle Moore, MD, lead researcher on the POEMS research and affiliate professor of medication at Cleveland Clinic. “Goserelin protects the ovaries from the consequences of chemotherapy, lowering the danger for early menopause. By getting these injections, extra girls grew to become pregnant with out negatively affecting their well being or their possibilities of surviving their most cancers.”

The outcomes are revealed within the present challenge of the Journal of the Nationwide Most cancers Institute. When the POEMS workforce introduced preliminary research outcomes on the 2014 American Society for Medical Oncology (ASCO) annual assembly, they gained worldwide consideration. POEMS is a singular collaboration, managed by SWOG, one in all 5 teams within the Nationwide Most cancers Institute’s Nationwide Medical Trials Community (NCTN), with assist from two different NCTN teams – ECOG-ACRIN Most cancers Analysis Group and the Alliance for Medical Trials in Oncology. The Worldwide Breast Most cancers Research Group, which incorporates the Australia New Zealand Breast Most cancers Trials Group, offered trial entry to sufferers around the globe.

The randomized, section III trial additionally obtained consideration for focusing not on the effectiveness of a most cancers remedy, however the affect that remedy has on the lives of most cancers survivors. In the US, virtually 49,000 girls beneath the age of 50 are recognized annually with invasive breast most cancers. Hormone-receptor detrimental breast most cancers is a much less frequent kind, which does not feed on estrogen or progesterone, and would not usually reply to medication that focus on these hormones.

Ovarian failure is one aspect impact of chemotherapy, one which carries a heavy burden for ladies, together with infertility, sexual dysfunction, and unsightly signs. To find out if ovarian failure might be prevented, the POEMS workforce launched their trial. Between 2004 and 2011, investigators randomized 218 premenopausal girls with hormone-receptor detrimental breast most cancers, putting them into two research teams. One group obtained normal chemotherapy remedy, and the opposite obtained normal chemotherapy plus goserelin.

Preliminary outcomes confirmed that 22 p.c of sufferers on normal remedy skilled ovarian failure whereas solely eight p.c who obtained goserelin did. As well as, these 2014 outcomes additionally confirmed that 12 p.c of sufferers on the usual arm obtained pregnant, whereas 22 p.c who obtained goserelin did.

The brand new outcomes, which embody 5 years of follow-up, present comparable results. On common, 23 p.c of girls who took goserelin grew to become pregnant in contrast with 12 p.c on the usual remedy. Importantly, girls who took goserelin skilled comparable, and even higher, survival charges in contrast with girls who obtained normal chemo. 5 years after remedy, 88 p.c of girls who took goserelin had been alive and disease-free in contrast with 79 p.c of girls who obtained normal chemo. Whereas variations in survival weren’t statistically important, 92 p.c of girls who took goserelin had been alive at 5 years in comparison with 83 p.c of management sufferers.

When the POEMS outcomes had been first issued, SWOG senior investigator Kathy Albain, MD, FACP, FASCO, of the Cardinal Bernardin Most cancers Middle of Loyola College Chicago, predicted they’d change the usual of look after breast most cancers. They usually have. The Nationwide Complete Most cancers Community Medical Apply Tips for Oncology and the St. Gallen Consensus Convention pointers already replicate the usage of goserelin for young women who hope to guard ovarian perform throughout chemotherapy for breast most cancers.

“Most cancers researchers got down to change the usual of care to be able to enhance, or lengthen, folks’s lives,” Moore stated. “Our remaining outcomes present a method to enhance high quality of life for younger girls with hormone-receptor detrimental breast most cancers. In the event that they wish to be moms, they’ll enhance their probabilities safely and successfully. I am pleased with this end result, and our worldwide workforce.”

Supply:

https://www.swog.org/news-events/information/2018/10/29/hormone-injections-reduce-early-menopause

Superior breast most cancers sufferers can profit from immunotherapy-chemotherapy mixture

Posted in News on 24th October 2018

Sufferers with an aggressive type of superior breast most cancers can profit from immunotherapy when utilized in mixture with chemotherapy as first-line therapy, in accordance with the outcomes of a giant worldwide Section III scientific trial printed at this time within the New England Journal of Drugs and led by a researcher on the UPMC Hillman Most cancers Middle and the College of Pittsburgh College of Drugs.

The research is the primary massive scientific trial to assist using immunotherapy in treating triple-negative breast most cancers and establishes a brand new commonplace of care in PD-L1+ sufferers, senior trial investigator and research writer Leisha Emens, M.D., Ph.D., co-leader of the UPMC Hillman Most cancers Immunology and Immunotherapy Program, defined. Outcomes have been introduced at this time on the annual assembly of the European Society for Medical Oncology in Munich, Germany.

Breast most cancers is the most typical most cancers in ladies, with an estimated 2 million new circumstances identified in 2018 alone. About 10 to 20 % of sufferers have triple-negative breast most cancers, an aggressive type of breast most cancers that has a better likelihood of recurrence and metastasis, and decrease survival.

“Whereas chemotherapy is the present commonplace of therapy for triple-negative breast most cancers, there’s an pressing want for newer, simpler therapies,” stated Emens. “The outcomes of this trial confirmed that including the immunotherapy drug atezolizumab to chemotherapy was well-tolerated and resulted in a transparent enhance in scientific profit for some sufferers with triple-negative breast most cancers.”

The IMpassion130 trial was designed to guage whether or not atezolizumab, authorised by the U.S. Meals and Drug Administration to deal with each bladder most cancers and non-small cell lung most cancers, could possibly be used together with chemotherapy to enhance scientific outcomes in sufferers with triple-negative breast most cancers. Atezolizumab belongs to a category of immunotherapy drugs often called checkpoint inhibitors. The drug targets the PD-L1 protein, which in triple-negative breast most cancers sufferers is discovered totally on immune cells that infiltrate the tumor. Blocking PD-L1 reinvigorates these immune cells, permitting them to assault the tumor.

The trial enrolled 902 sufferers with both metastatic or regionally superior triple-negative breast most cancers that would not be surgically eliminated. Sufferers have been enrolled at 246 websites in 41 international locations the world over and have been randomly assigned to obtain both atezolizumab or a placebo, together with the chemotherapy drug nab-paclitaxel.

Each progression-free survival–the size of time the affected person lives after receiving the remedy with out the tumor rising or spreading, and total survival–the size of time the affected person survives from the beginning of the trial, have been recorded.

Within the total affected person inhabitants, the researchers discovered a statistically important enhance in progression-free survival in sufferers handled with each nab-paclitaxel and atezolizumab – 7.2 months when in comparison with 5.5 months in sufferers who acquired chemotherapy alone. Within the group of sufferers who expressed the PD-L1 protein on tumor-infiltrating immune cells, the mixture therapy had a extra important influence on progression-free survival – 7.5 months versus 5 months.

General survival was 21.three months within the mixture therapy group as in comparison with 17.6 months with chemotherapy alone, although this didn’t attain statistical significance on this first evaluation. Within the group of sufferers who expressed PD-L1 on their tumors, the distinction in survival was better, with total survival of 25 months, in distinction to 15.5 months in sufferers handled with nab-paclitaxel alone.

“This enchancment in progression-free and total survival is clinically significant in sufferers with superior PD-L1+ triple-negative breast most cancers,” Emens stated. The researchers proceed to observe the sufferers to find out total survival over an extended time interval.

The adversarial occasions noticed have been much like the identified adversarial occasion profile of the 2 medication. Sufferers who acquired each immunotherapy and nab-paclitaxel skilled a better frequency of adversarial occasions that have been doubtlessly immune-related, than those that acquired chemotherapy alone, at 7.5 % versus four.three %, respectively.

The trial was funded by F. Hoffmann-La Roche/Genentech, which offered atezolizumab and placebo and collaborated with a tutorial steering committee concerning the trial design and information assortment, evaluation and interpretation. Celgene offered nab-paclitaxel and had no position within the trial design, information assortment or evaluation, however did evaluation the manuscript.

A whole itemizing of the authors and their affiliations, together with the monetary disclosure varieties offered by the authors may be discovered with the article on-line.

Supply:

https://www.upmc.com/media/information/102018-emens-nejm-trial

Purdue Pharma, Eisai announce constructive topline outcomes from Part three examine of lemborexant

Posted in News on 19th October 2018

Eisai Co., Ltd. and Purdue Pharma L.P. introduced constructive topline outcomes from SUNRISE 2, a long-term Part three efficacy and security analysis of lemborexant, an investigational agent for sleep-wake regulation at the moment being studied for the potential remedy of a number of sleep-wake problems. Topline outcomes reported right this moment are the first and key secondary outcomes of the examine from the six-month, placebo-controlled remedy interval; the examine is ongoing to 12 months. Eisai and Purdue Pharma plan to current full outcomes from SUNRISE 2 at upcoming medical conferences in 2019.

SUNRISE 2 enrolled greater than 900 grownup sufferers (18 to 88 years of age) with insomnia dysfunction, characterised by issue falling asleep and/or staying asleep. The examine met the pre-specified main and key secondary efficacy goals assessed by affected person self-reports (sleep diaries). On the finish of the six-month, placebo-controlled remedy interval, lemborexant 5 mg and 10 mg offered statistically vital enchancment in subjective sleep onset latency in comparison with placebo, the examine’s main endpoint. Lemborexant 5 mg and 10 mg additionally offered statistically vital enchancment in sleep upkeep variables of subjective sleep effectivity and subjective wake after sleep onset in comparison with placebo, which have been the examine’s key secondary endpoints. Day by day functioning, as measured by the Insomnia Severity Index, was additionally improved by each lemborexant 5 mg and 10 mg in comparison with placebo. General discontinuation charges on account of AEs have been comparable between placebo and lemborexant 5 mg, and better for lemborexant 10 mg.

“As a clinician and researcher treating sufferers with insomnia and different sleep-wake problems for 30 years, for me, profitable remedy signifies that sufferers go to sleep quick, sleep nicely, and wake nicely, with out practical impairment, or lack of impact over time,” stated Russell Rosenberg, PhD, D.ABSM, a Principal Investigator within the lemborexant research and former Chairman of the Board of the Nationwide Sleep Basis. “The outcomes of SUNRISE 2 are notably encouraging for the numerous sufferers that suffer from persistent insomnia.”

The outcomes of SUNRISE 2 construct on a rising physique of information supporting the event of lemborexant, together with SUNRISE 1, a zolpidem tartrate prolonged launch in addition to key security research evaluating for impairment as assessed by the power to keep up postural stability – a predictor of danger for falls – after middle-of-the-night and subsequent morning awakening and next-morning driving efficiency.

“Our aspiration for lemborexant is to carry to the hundreds of thousands of sufferers affected by insomnia and different sleep- wake problems an agent for sleep-wake regulation that improves their capacity to go to sleep and keep asleep, and maintains efficacy over time,” stated Lynn Kramer, MD, Chief Medical Officer and Chief Medical Officer, Neurology Enterprise Group, Eisai. “In SUNRISE 2, lemborexant improved time to sleep onset and sleep upkeep over a six-month interval. With these outcomes, we now look ahead to continuing with regulatory submissions for lemborexant to carry to sufferers a long-term remedy possibility for treating the sleep-wake dysfunction, insomnia.”

Lemborexant seems to impression the underlying motive for a affected person’s incapability to sleep nicely. Lemborexant acts on the orexin neurotransmitter system and is believed to control sleep and wake by dampening wakefulness with out impeding the power to awaken to exterior stimuli.
“These lemborexant examine outcomes for sleep onset and sleep upkeep are important elements of the sleep-wake paradigm for these affected by insomnia,” stated Marcelo Bigal, MD, PhD, Chief Medical Officer, Purdue Pharma. “We perceive the significance of sleep-wake regulation to general well being and affected person outcomes and, alongside our collaboration companion, Eisai, look ahead to continued analysis as a part of our dedication to a wide range of affected person populations with sleep-wake problems.”

Found by Eisai, lemborexant is being collectively developed by Eisai and Purdue Pharma. Details about ongoing medical research is obtainable at clinicaltrials.gov.

This launch discusses investigational makes use of of an agent in improvement and isn’t supposed to convey conclusions about efficacy or security. There is no such thing as a assure that such investigational agent will efficiently full medical improvement or achieve well being authority approval.

Supply:

https://www.eisai.com/information/2018/information201885.html

Arcus Biosciences declares presentation of ultimate outcomes from Part 1 research of AB928 at ESMO 2018

Posted in News on 12th October 2018

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical firm centered on creating progressive most cancers immunotherapies, immediately introduced that it’s going to current last outcomes from the Part 1 research of AB928, its twin adenosine receptor antagonist, in wholesome volunteers throughout a poster show session on the European Society of Medical Oncology (ESMO) 2018 Congress, being held October 19-23, 2018, in Munich, Germany. The security knowledge to be introduced will reveal that on this research, there was no proof of the physiological results of blocking adenosine which were noticed clinically with earlier adenosine receptor antagonists. Physiological results related to the sooner adenosine receptor antagonists that have been initially designed for CNS indications could doubtlessly restrict their optimum dosing within the oncology setting.

The pharmacokinetic and pharmacodynamic correlations generated from this research, which will probably be described within the poster presentation, have been used to information dose choice within the Firm’s 4 Part 1/1b trials in sufferers.

Particulars of the poster presentation are as follows:

Summary Quantity: 1880P
Poster Title: Ultimate outcomes of the Part 1 research in wholesome volunteers of AB928, a twin antagonist of the A2aR and A2bR adenosine receptors being studied as an activator of anti-tumor immune response.
Poster show session: Biomarkers, Gynecological cancers, Hematological malignancies, Immunotherapy of most cancers, New diagnostic instruments, NSCLC – early stage, regionally superior & metastatic, SCLC, Thoracic malignancies, Translational analysis (ID 259)
Session Date and Time: Saturday, Oct. 20, 2018, 12:30 – 1:30 pm CEST
Location: Corridor A3

Supply: